
CRS and ICANS Show Low Severity With Bispecifics in Multiple Myeloma
Douglas W. Sborov, MD, MS Director, Hematology Disease Center and Plasma Cell Dyscrasias Program Co-Leader, Hematologic Malignancies Clinical Trials Research Group Associate Professor University of Utah—Huntsman Cancer Institute Salt Lake City, UT Targeted …